- Vivir con FSHD
-
- Participa
-
- Investigación y asistencia clínica
- Quiénes somos
- Noticias y medios de comunicación
- Eventos
- Blog
- BetterLife
- Donar hoy
Yesterday, Novartis shared an update on delpacibart braxlosiran (del-brax), an investigational treatment for FSHD. Following discussions with the U.S. Food and Drug Administration (FDA), Novartis reports that the design of its Phase 3 clinical trial is aligned with the agency’s expectations, with results now anticipated in 2029. The company also indicated that it will continue exploring opportunities for a potential accelerated approval pathway.
There are currently no approved treatments for FSHD. Del-brax is designed to address the underlying cause of the disease by reducing the production of DUX4, a protein whose abnormal expression damages muscle in people with FSHD. Del-brax was originally developed by Avidity Biosciences, which Novartis acquired in February 2026.
In June, Novartis anunciado encouraging results from FORTITUDE, a Phase 1/2 clinical trial. Del-brax met its primary and key secondary biomarker endpoints, with participants receiving the treatment showing reductions in KHDC1L, a blood marker associated with DUX4 activity, and creatine kinase (CK), a marker of muscle damage.
Novartis has also reported encouraging trends across several clinical measures. While these early findings offer reason for optimism, additional data are needed to determine whether del-brax can meaningfully slow the progression of FSHD.
Del-brax is now being evaluated in FORTITUDE-3, a Phase 3 clinical trial involving approximately 200 people with FSHD, ages 16 to 70, at sites in the U.S. and around the world. Phase 3 trials are larger studies designed to learn whether a treatment is safe and effective, and results can provide the evidence regulators need to make approval decisions.
We know many in our community wanted answers sooner. Following the encouraging results earlier this year, there was hope that del-brax might reach people living with FSHD on a faster timeline. This news is difficult, especially for those living with this relentlessly progressive disease. Time matters. FSHD does not wait.
We believe the urgency of this disease must remain central to every conversation about treatment development and approval.
On November 19, Novartis provided additional context about its discussions with the FDA. According to the company, the FDA was encouraged by the data presented but highlighted the challenge of evaluating treatments for a disease like FSHD. The one-year data did not yet show enough change in the trial’s measures of disease progression, especially for participants receiving a placebo, to clearly show a difference between the treatment and placebo groups.
Novartis explained that the FDA is looking for longer-term clinical data to better understand the treatment’s potential effects on disease measures. In response, the company is strengthening its Phase 3 study, including extending the study to 36 months.
These changes are intended to build stronger evidence of whether del-brax provides meaningful clinical benefits. While they extend the anticipated timeline for Phase 3 results to 2029, they may also help establish a stronger foundation for regulatory review.
For full details, view the webcast of Novartis’ November 19 investor presentation.
Novartis indicated that the possibility of an accelerated approval pathway remains open. The company expects to review additional two-year data from their ongoing Phase 1/2 study in 2027 and reengage the FDA based on those findings.
Accelerated approval is a regulatory process that can allow treatments for serious diseases to reach patients sooner, based on evidence that a treatment is reasonably likely to predict clinical benefit, while longer confirmatory trials are being completed.
Whether this pathway will be available for del-brax remains uncertain, though Novartis reported that the FDA was encouraged by the data presented so far. Novartis continues to explore this possibility while advancing its Phase 3 trial.
Bringing a treatment to people with FSHD requires more than promising science. It requires the evidence needed to demonstrate that those treatments are safe and effective. Developing treatments for a complex disease takes rigorous science and meaningful clinical evidence. Every study, every trial participant, and every new finding helps build the knowledge needed to bring effective treatments to the FSHD community.
And while we cannot eliminate every obstacle, we are working to ensure that the path to approval is as clear and efficient as possible. Through initiatives like our Industry Collaborative, the FSHD Society works with drug developers, researchers, clinicians, and people living with FSHD to strengthen the data and standards regulators need to evaluate treatments and advance an understanding of FSHD as one disease.
Our goal is not simply to see treatments succeed in clinical trials. It is to help ensure that safe, effective treatments can be approved and reach everyone who needs them.
Our resolve has not changed. It is shared with and driven by those living with FSHD and their families, by the researchers and clinicians who study it, by companies investing in FSHD treatments, and by all of us at the FSHD Society. This effort has always been, and continues to be, the work of an entire community.
We will continue to share updates as more information becomes available.